T1	Participants 34 101	patients receiving androgen deprivation therapy for prostate cancer
T2	Participants 356 410	patients with prostate cancer during androgen ablation
T3	Participants 753 848	Forty-eight osteoporotic patients with prostate cancer, treated with 3-month depot triptorelina
T4	Participants 1216 1268	All patients also received bicalutamide for 4 weeks.
T5	Participants 2227 2264	men receiving ADT for prostate cancer
